Analysts from Citi and Barclays revised their price targets for TNDM following reduced full-year revenue guidance despite strong Q3 results. Citi's Joanne Wuensch reduced her target from $23 to $18, while Barclays' Matt Miksic, citing poor international sales, lowered his target from $62 to $39.
Tandem Diabetes Care股票讨论
只需查看通话选项即可。它们很昂贵
但是,股价仅波动5-10%,没有消息。幕后发生了什么?!
随着 GLP-1 减肥药公司影响力的增强,它们已成长为股市的新领导者。
$诺和诺德(NVO.US)$ 旗下有Wegovy和Ozempic,现在是欧洲最大的公司,市值为4,330亿美元,这家丹麦制药巨头的快速增长甚至对丹麦克朗的汇率和利率产生了直接影响。
与此同时, $礼来(LLY.US)$ ,其中...
对收益/指导的回应:
• $GoodRx(GDRX.US)$ +38.5%, $EDGIO(EGIO.US)$ +13.5%, $Lemonade(LMND.US)$ +10.7%, $Desktop Metal(DM.US)$ +8.5%, $ShockWave Medical(SWAV.US)$ +8.2%, $Pubmatic(PUBM.US)$ +8.1%, $Olaplex(OLPX.US)$ +7%, $Vivid Seats(SEAT.US)$ +6.4%, $Noble(NE.US)$ +6.3%, $艾斯本科技(AZPN.US)$ +5.4%, $艾伦建材(AAON.US)$ +5%, $Hudbay Minerals(HBM.US)$ +5%, $Vivint Smart Home(VVNT.US)$ +4.9%, $Vivint Smart Home(VVNT.US)$ +4...
暂无评论